Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1

(2014) M. Mraz et al.   BLOOD

Daratumumab granted breakthrough drug status

(2014) Jacob P Laubach et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

(2014) Saskia Meyer et al.   mAbs

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

(2013) Allan Lipton et al.   BREAST CANCER RESEARCH AND TREATMENT

Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance

(2013) S. J. de Haart et al.   CLINICAL CANCER RESEARCH

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Cancer's true breakthroughs

(2013) Elie Dolgin   NATURE MEDICINE

Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL

(2012) Yuhko Suzuki et al.   ANNALS OF HEMATOLOGY

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma

(2012) R. W. J. Groen et al.   BLOOD

Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis

(2012) Sambasiva P. Rao et al.   PLoS One

CD38 and chronic lymphocytic leukemia: a decade later

(2011) F. Malavasi et al.   BLOOD

rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia

(2011) X. Ge et al.   CLINICAL CANCER RESEARCH

Editorial: CD38 and retinoids: a step toward a cure

(2011) Fabio Malavasi   JOURNAL OF LEUKOCYTE BIOLOGY

All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-δ

(2011) Akira Uruno et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

(2011) N W C J van de Donk et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

(2011) M S van der Veer et al.   Blood Cancer Journal

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab

(2010) Allan Lipton et al.   CANCER

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

(2010) Niels W.C.J. van de Donk et al.   CANCER TREATMENT REVIEWS

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

(2010) M. S. van der Veer et al.   HAEMATOLOGICA

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells

(2010) T Vaisitti et al.   LEUKEMIA

An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy

(2009) Y. Mishima et al.   CLINICAL CANCER RESEARCH

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival

(2008) N. A. Johnson et al.   BLOOD